Anturane TIA Italian Study "ATIAIS"


Phase N/A Results


No significant difference in the incidence of events was observed between the two treatments at the end of the follow-up period. Analysis of the results according to sex showed that male patients treated with ASA had a significant benefit (p < 0.001) with a 53% risk reduction for further events. In female patients, sulfinpyrazone showed a favorable trend which was not statistically significant.